Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives

Roberto Iacovelli, Carlo Maria Cicala, Chiara Ciccarese, Emilio Sacco, Marco Racioppi, Pierfrancesco Bassi, Giampaolo Tortora

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Metastatic urothelial carcinoma (mUC) is a lethal disease for which platinum-based chemotherapy represents the standard of care; however, long-term survival is achieved only in a minority of patients. Recently, along with important advances in the comprehension of the biology of this disease, the treatment paradigm of mUC has undergone a rapid expansion with the approval of several immune-checkpoint inhibitors (ICIs) and targeted agents in both first- and second-line settings. Cisplatin-based chemotherapy remains the backbone of first-therapy for mUC; nevertheless, for those patients who do not progress after the full course of first-line chemotherapy, maintenance treatment with the anti-PD-L1 avelumab showed to prolong overall survival compared observation alone. Moreover, the disappointing results of chemotherapy in pre-treated patients have led to the investigation and the subsequent approval of the anti-PD-1 pembrolizumab, which showed an unprecedented survival benefit when compared to second-line chemotherapy. Recently, target therapy with the antibody-drug conjugate (ADC) enfortumab vedotin, directed against Nectin-4, showed outstanding results in patients treated with both chemotherapy and immunotherapy. The FGFR inhibitor erdafitinib and sacituzumab govitecan, an ADC targeting Trop-2, demonstrated encouraging activity in phase II studies and are currently under investigation in randomized phase III trials. ICIs and targeted therapies also demonstrated promising results as first-line treatment of cisplatin-ineligible patients; randomized trials of ICIs alone or in combination with targeted agents are ongoing and may broaden the therapeutic armamentarium for this category of patients. In this review, we describe the current state of art for the treatment of mUC; in addition, we present the latest evidences from the most recent literature and congress presentations. Finally, we illustrate the key ongoing clinical trials, focusing on ICIs and target therapies.
Lingua originaleEnglish
pagine (da-a)3-10
Numero di pagine8
RivistaUrologia
Volume90
DOI
Stato di pubblicazionePubblicato - 2023

Keywords

  • FGFR
  • Urothelial cancer
  • new therapies
  • erdafitinib
  • immunotherapy
  • enfortumab vedotin

Fingerprint

Entra nei temi di ricerca di 'Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives'. Insieme formano una fingerprint unica.

Cita questo